Coya Therapeutics, Inc.
HealthcareNASDAQ:COYA · NASDAQ Capital Market
+$0.10 today
Vol 0.11M · Avg 0.16M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-49.3%
avg -18.5%
ROIC
-46.0%
avg -78.2%
ROA
-42.5%
avg -59.3%
Analysis
ROA is currently the strongest return metric at -42.5% versus its period average of -59.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Arun Swaminathan | Chief Executive Officer & Director | $941,850.00 | — | 57 | $293,983.00 | 1.61% |
Fred Grossman FAPA | President & Chief Medical Officer | $787,093.00 | — | 67 | $140,041.00 | 0.77% |
David S. Snyder | Chief Financial Officer & Chief Operating Officer | $698,360.00 | — | 66 | $140,041.00 | 0.77% |
Michelle Frazier | Senior Vice President of Regulatory | — | — | — | — | — |
Aaron Thome | Head of Neuroinflammation Platform | — | — | — | — | — |
Karen King | Senior Vice President of Program Management & Clinical Operations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | -19.1% (6yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Forward estimates point to Revenue at -19.1% (6yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Immix Biopharma, Inc.
NASDAQ:IMMX
$459.70M
Ovid Therapeutics Inc.
NASDAQ:OVID
$303.33M
Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTL
$266.95M
MacroGenics, Inc.
NASDAQ:MGNX
$251.71M
Shattuck Labs, Inc.
NASDAQ:STTK
$236.64M
Whitehawk Therapeutics Inc
NASDAQ:WHWK
$205.72M
Oramed Pharmaceuticals Inc.
NASDAQ:ORMP
$158.38M
Context Therapeutics Inc.
NASDAQ:CNTX
$127.71M
Pliant Therapeutics, Inc.
NASDAQ:PLRX
$69.97M
Clene Inc.
NASDAQ:CLNN
$60.20M
Who manages COYA?
Coya Therapeutics, Inc. (COYA) lists 6 active executives. The top listed executive is David S. Snyder, Chief Financial Officer & Chief Operating Officer.
Are COYA insiders buying or selling?
Recent insider activity shows net buying of $12.69M.
Explore More
Continue the stock analysis
Jump to another research area for this company.